000			03116nam a22003137a 4500
999			_c12284 _d12284
001			OB 2021 0002
003			PILC
005			20240720153244.0
008			220427b xxu||||| |||| 00| 0 eng d
040			_beng _cFEU-NRMF MEDICAL LIBRARY _erda
041			_aenglish
050			_aOB 2021 0002
245			_aA Comparative study on the effect of micronized progesterone and oral dydrogesterone in the treatment of threatened abortion in a tertiary medical center from 2015 to 2019 / _cDenise Elaine A. Reyes; Lylah Reyes; Elizabeth Ahyong-Reyes.
260			_aFairview, Quezon City: _bDepartment of Obstetrics and Gynecology, FEU-NRMF, _c2021.
300			_a40 pages: _billustrations, tables; _c(in folder) + _ewith flash drive (soft copy).
336			_2rdacontent _atext
337			_2rdamedia _aunmediated
338			_2rdacarrier _avolume
504			_aIncludes appendices and bibliographical references.
520			_aAbstract: Threatened abortion occurs in 15% of pregnancies. If not prevented this may lead to pregnancy loss in 20% of cases. But with its resolution, it may lead to a better pregnancy outcome. Progesterone plays a key role in the prevention and management of threated abortion. To determine whether vaginal micronized progesterone is comparable with oral dydrogesterone in the treatment of Threatened abortion. This is a retrospective cohort study involving 573 charts of pregnant patients with threatened abortion who were either given oral dydrogesterone or vaginal micronized progesterone as treatment. Both out- and in-patient charts were reviewed and data extracted by the primary investigator. Baseline maternal characteristics gathered were compared between the two arms. The resolution of symptoms, duration of treatment, occurrence of adverse effects and pregnancy outcome were compared and analyzed between the type of progesterone using chi square and t-test. The resolution of signs and/or symptoms for patients with threatened abortion was not significantly different between those given vaginal micronized progesterone versus those who took oral dydrogesterone (p=0.401). The length of treatment ranged from 7 to 14 days to achieve resolution of signs and/or symptoms. A significantly higher proportion of cases in the oral dydrogesterone arm had nausea and somnolence, while increased vaginal discharge was noted in the vaginal progesterone group (p=0.001). The use of vaginal micronized progesterone and oral dydrogesterone achieved resolution of signs and/or symptoms of threatened abortion generally within 7 days but can be extended for 14 days. Systemic adverse effects of nausea and somnolence were more common in oral dydrogesterone. With micronized progesterone, because of its route of administration, vaginal discharge was more often observed.
521			_aRESDOG
650			_athreatened abortion
650			_adydrogesterone
650			_amicronized progesterone
700			_aReyes, Denise Elaine A., MD. _eprincipal investigator
700			_aReyes, Lylah D., MD. _eco-author
700			_aAhyong-Reyes, Elizabeth, MD. _eco-author
942			_2lcc _cRU